UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
In a report published Thursday, Credit Suisse analyst Jason Kantor downgraded the rating on Infinity Pharmaceuticals (NASDAQ: INFI) from Outperform to Neutral, but reiterated the $20.00 price target.
In the report, Credit Suisse noted, “We are downgrading INFI to Neutral because (1) limited clinical data is expected in 2014, (2) an increasingly complex competitive landscape, which we think is evolving to favor BTK inhibitors and ABT-199 over PI3K inhibitors; and (3) risk of class effect safety issues or drug specific safety issues, although initial concerns over infections and liver enzymes seem to have cooled down.”
Infinity Pharmaceuticals closed on Wednesday at $13.31.
Latest Ratings for INFI
|Jun 2016||Morgan Stanley||Downgrades||Overweight||Equal-Weight|
|Jun 2016||William Blair||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.